INDV Stock — Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. (INDV)

Updated October 16, 2026.

INDV is a Stock. Total return is 217.0% over the past 11.8 years, 126.8 points behind SPY at 343.8%.

Indivior Pharmaceuticals develops, manufactures, and sells buprenorphine-based prescription medications for treating opioid use disorder, with marketed products including SUBLOCADE extended-release injections and SUBOXONE Film, along with a pipeline including selective orexin-1 receptor antagonist candidates. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to the pharmaceutical and specialty healthcare sector, particularly those focused on addiction medicine and treatment.

INDV performance versus SPY

Price and return data through 2026-10-16.

Total return is 217.0% over the past 11.8 years, 126.8 points behind SPY at 343.8%. Over the past year its total return — price change plus distributions reinvested — is 31.4%. Its deepest 1-year drawdown was 22.4%.

INDV key facts

Asset type

Stock

Asset class

Equity

Inception date

12/29/2014

Distribution frequency

None

Last close

$32.45 (as of 2026-10-16)

Market cap

$3,830,136,258

Average volume

4291100.0

Ex-dividend date

10/30/2026

Payment date

11/06/2026

Beta

1.177

Payout ratio

2.2%

P/E ratio

11.63

Forward P/E

9.4607

EPS

$2.79

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INDV risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 22.4%.

Who may consider INDV — and who may not

It is a weaker fit for investors who need monthly cash flow (INDV does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on INDV

• All tickers starting with I

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions